. Preclinical characterization of RO4602522, a novel, selective and orally active monoamine oxidase type B inhibitor for the treatment of Alzheimer's disease. Alzheimers Dement. 2013 Jul;9(4 Suppl):P818,

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Sembragiline